Cargando…

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Bow, Eric J, Vanness, David J, Slavin, Monica, Cordonnier, Catherine, Cornely, Oliver A, Marks, David I, Pagliuca, Antonio, Solano, Carlos, Cragin, Lael, Shaul, Alissa J, Sorensen, Sonja, Chambers, Richard, Kantecki, Michal, Weinstein, David, Schlamm, Haran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374298/
https://www.ncbi.nlm.nih.gov/pubmed/25887385
http://dx.doi.org/10.1186/s12879-015-0855-6
_version_ 1782363467194302464
author Bow, Eric J
Vanness, David J
Slavin, Monica
Cordonnier, Catherine
Cornely, Oliver A
Marks, David I
Pagliuca, Antonio
Solano, Carlos
Cragin, Lael
Shaul, Alissa J
Sorensen, Sonja
Chambers, Richard
Kantecki, Michal
Weinstein, David
Schlamm, Haran
author_facet Bow, Eric J
Vanness, David J
Slavin, Monica
Cordonnier, Catherine
Cornely, Oliver A
Marks, David I
Pagliuca, Antonio
Solano, Carlos
Cragin, Lael
Shaul, Alissa J
Sorensen, Sonja
Chambers, Richard
Kantecki, Michal
Weinstein, David
Schlamm, Haran
author_sort Bow, Eric J
collection PubMed
description BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for prophylaxis in alloHCT recipients, with the goal of informing medical decision-making. METHODS: Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence of IFI/invasive aspergillosis/invasive candidiasis, all-cause mortality, and use of other antifungals) were extracted from eligible RCTs and incorporated into a Bayesian hierarchical random-effects MTC. RESULTS: Five eligible RCTs, randomizing 2147 patients in total, were included. Relative to fluconazole, prophylaxis with itraconazole (odds ratio [OR]: 0.52; interquartile range [IQR]: 0.35–0.76), posaconazole (OR: 0.56; IQR: 0.32–0.99), and voriconazole (OR: 0.46; IQR: 0.28–0.73) reduced incidence of overall proven/probable IFI. Posaconazole (OR: 0.31; IQR: 0.17–0.58) and voriconazole (OR: 0.33; IQR: 0.17–0.58) prophylaxis reduced proven/probable invasive aspergillosis more than itraconazole (OR: 0.68; IQR: 0.42–1.12). All-cause mortality was similar across all mould-active agents. CONCLUSION: As expected, mould-active azoles prevented IFIs, particularly invasive aspergillosis, more effectively than fluconazole in alloHCT recipients. The paucity of comparative efficacy data suggests that other factors such as long-term tolerability, availability of intravenous formulations, local IFI epidemiology, and drug costs may need to form the basis for selection among the mould-active azoles. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0855-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4374298
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43742982015-03-27 Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients Bow, Eric J Vanness, David J Slavin, Monica Cordonnier, Catherine Cornely, Oliver A Marks, David I Pagliuca, Antonio Solano, Carlos Cragin, Lael Shaul, Alissa J Sorensen, Sonja Chambers, Richard Kantecki, Michal Weinstein, David Schlamm, Haran BMC Infect Dis Research Article BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for prophylaxis in alloHCT recipients, with the goal of informing medical decision-making. METHODS: Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence of IFI/invasive aspergillosis/invasive candidiasis, all-cause mortality, and use of other antifungals) were extracted from eligible RCTs and incorporated into a Bayesian hierarchical random-effects MTC. RESULTS: Five eligible RCTs, randomizing 2147 patients in total, were included. Relative to fluconazole, prophylaxis with itraconazole (odds ratio [OR]: 0.52; interquartile range [IQR]: 0.35–0.76), posaconazole (OR: 0.56; IQR: 0.32–0.99), and voriconazole (OR: 0.46; IQR: 0.28–0.73) reduced incidence of overall proven/probable IFI. Posaconazole (OR: 0.31; IQR: 0.17–0.58) and voriconazole (OR: 0.33; IQR: 0.17–0.58) prophylaxis reduced proven/probable invasive aspergillosis more than itraconazole (OR: 0.68; IQR: 0.42–1.12). All-cause mortality was similar across all mould-active agents. CONCLUSION: As expected, mould-active azoles prevented IFIs, particularly invasive aspergillosis, more effectively than fluconazole in alloHCT recipients. The paucity of comparative efficacy data suggests that other factors such as long-term tolerability, availability of intravenous formulations, local IFI epidemiology, and drug costs may need to form the basis for selection among the mould-active azoles. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0855-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-17 /pmc/articles/PMC4374298/ /pubmed/25887385 http://dx.doi.org/10.1186/s12879-015-0855-6 Text en © Bow et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bow, Eric J
Vanness, David J
Slavin, Monica
Cordonnier, Catherine
Cornely, Oliver A
Marks, David I
Pagliuca, Antonio
Solano, Carlos
Cragin, Lael
Shaul, Alissa J
Sorensen, Sonja
Chambers, Richard
Kantecki, Michal
Weinstein, David
Schlamm, Haran
Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
title Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
title_full Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
title_fullStr Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
title_full_unstemmed Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
title_short Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
title_sort systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374298/
https://www.ncbi.nlm.nih.gov/pubmed/25887385
http://dx.doi.org/10.1186/s12879-015-0855-6
work_keys_str_mv AT bowericj systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT vannessdavidj systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT slavinmonica systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT cordonniercatherine systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT cornelyolivera systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT marksdavidi systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT pagliucaantonio systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT solanocarlos systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT craginlael systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT shaulalissaj systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT sorensensonja systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT chambersrichard systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT kanteckimichal systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT weinsteindavid systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients
AT schlammharan systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients